Novel MmpL3 Inhibitor as a Treatment of Mycobacterium Tuberculosis


Executive Summary


Mycobacterium Tuberculosis (Mtb) is the pathogen responsible for Tuberculosis. Standard TB treatments typically require four different drugs and a duration of six to nine months of treatment; however, there is still an evolution of drug-resistant Mtb. With not only Tuberculosis, but drug-resistant Tuberculosis causing upwards of 1.5 million deaths annually, there is a clear unaddressed need to develop novel drugs to combat TB. Our researchers at MSU have identified a molecule capable of killing TB when other drugs may not be able to. This drug has the potential to drastically improve the antibiotic cocktail currently administered to treat TB.


Description of Technology


A new class of MmpL3 inhibitors that has a distinct chemical structure and demonstrated abilities to kill Mycobacterium Tuberculosis. MmpL3 is a validated drug target that is essential for mTB’s cell viability. Now, MSU researchers have discovered new MmpL3 inhibitors which reduces mycolic acid biosynthesis of the Mycobacterium Tuberculosis ultimately killing the bacterium.


Key Benefits

•       MmpL3 chemical inhibitor

•       Small molecule drug targeting validated target



•       Enhancer of Mtb treatment

•       Reduce duration of treatment


Patent Status: 


Under Review.


Licensing Rights Available


Full licensing rights available.


Inventors: Robert Abramovitch, Huiqing Zheng


Tech ID: TEC2018-0055


Patent Information:

For Information, Contact:

Su-Jun Lim
Technology Manager
Michigan State University